AccuraGen, A US-China Cancer Diagnostics Company, Raises $40 Million

2016-06-01 00:00:00

AccuraGen Holdings, a US-China cancer diagnostics company, has closed a $40 million Series B financing. AccuraGen develops blood tests that sequence cell free DNA (cfDNA) to provide sensitive and accurate cancer diagnostics. Its current product, which is undergoing clinical tests in China, is a 61-gene assay. Participants in the Series B include Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford‐StartX Fund, and Nan Fung Capital, along with existing Series A investors.  More details....

External Event...